259 related articles for article (PubMed ID: 30325319)
1. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
2. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
3. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.
Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123
[TBL] [Abstract][Full Text] [Related]
4. High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients.
Masaki T; Wang Y; DiGiovanna JJ; Khan SG; Raffeld M; Beltaifa S; Hornyak TJ; Darling TN; Lee CC; Kraemer KH
Pigment Cell Melanoma Res; 2014 May; 27(3):454-64. PubMed ID: 24483290
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan.
Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY
J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048
[TBL] [Abstract][Full Text] [Related]
6. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
Tschandl P; Berghoff AS; Preusser M; Burgstaller-Muehlbacher S; Pehamberger H; Okamoto I; Kittler H
PLoS One; 2013; 8(7):e69639. PubMed ID: 23861977
[TBL] [Abstract][Full Text] [Related]
7. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
8. Molecular Genomic Profiling of Melanocytic Nevi.
Colebatch AJ; Ferguson P; Newell F; Kazakoff SH; Witkowski T; Dobrovic A; Johansson PA; Saw RPM; Stretch JR; McArthur GA; Long GV; Thompson JF; Pearson JV; Mann GJ; Hayward NK; Waddell N; Scolyer RA; Wilmott JS
J Invest Dermatol; 2019 Aug; 139(8):1762-1768. PubMed ID: 30772300
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.
Tseng D; Kim J; Warrick A; Nelson D; Pukay M; Beadling C; Heinrich M; Selim MA; Corless CL; Nelson K
J Am Acad Dermatol; 2014 Aug; 71(2):229-36. PubMed ID: 24842760
[TBL] [Abstract][Full Text] [Related]
10. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
[TBL] [Abstract][Full Text] [Related]
11. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
12. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation.
Venesio T; Chiorino G; Balsamo A; Zaccagna A; Petti C; Scatolini M; Pisacane A; Sarotto I; Picciotto F; Risio M
Mod Pathol; 2008 Jun; 21(6):716-26. PubMed ID: 18408659
[TBL] [Abstract][Full Text] [Related]
13. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
15. Mutational profiling of acral melanomas in Korean populations.
Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
[TBL] [Abstract][Full Text] [Related]
16. The genomic landscape of childhood and adolescent melanoma.
Lu C; Zhang J; Nagahawatte P; Easton J; Lee S; Liu Z; Ding L; Wyczalkowski MA; Valentine M; Navid F; Mulder H; Tatevossian RG; Dalton J; Davenport J; Yin Z; Edmonson M; Rusch M; Wu G; Li Y; Parker M; Hedlund E; Shurtleff S; Raimondi S; Bhavin V; Donald Y; Mardis ER; Wilson RK; Evans WE; Ellison DW; Pounds S; Dyer M; Downing JR; Pappo A; Bahrami A
J Invest Dermatol; 2015 Mar; 135(3):816-823. PubMed ID: 25268584
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi.
Salgado CM; Basu D; Nikiforova M; Bauer BS; Johnson D; Rundell V; Grunwaldt LJ; Reyes-Múgica M
Pediatr Dev Pathol; 2015; 18(1):1-9. PubMed ID: 25490715
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
20. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
